Quick Answer
LIGAND PHARMACEUTICALS INC reported Cash and Equivalents of $174.93 million for fiscal year 2025.
LIGAND PHARMACEUTICALS INC Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $174.93M | +141.9% |
| 2024 | $72.31M | +215.0% |
| 2023 | $22.95M | -49.0% |
| 2022 | $45.01M | +130.5% |
| 2021 | $19.52M | -59.0% |
| 2020 | $47.62M | -33.4% |
| 2019 | $71.54M | -38.9% |
| 2018 | $117.16M | +468.2% |
| 2017 | $20.62M | +10.0% |
| 2016 | $18.75M | -80.8% |
| 2015 | $97.43M | -39.2% |
| 2014 | $160.20M | +1276.4% |
| 2013 | $11.64M | -6.0% |
| 2012 | $12.38M | +75.8% |
| 2011 | $7.04M | +110.4% |
| 2010 | $3.35M | -79.1% |
| 2009 | $16.03M | -44.2% |
| 2008 | $28.75M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $139.38M | +119.1% | +106.0% |
| June 30, 2025 | $67.67M | +273.1% | +41.0% |
| March 31, 2025 | $47.99M | -4.2% | -33.6% |
| December 31, 2024 | $72.31M | +215.0% | +13.7% |
| September 30, 2024 | $63.62M | +230.1% | +250.7% |
| June 30, 2024 | $18.14M | -36.2% | -63.8% |
| March 31, 2024 | $50.09M | -43.5% | +118.2% |
| December 31, 2023 | $22.95M | -49.0% | +19.1% |
- LIGAND PHARMACEUTICALS INC showed an increase of +141.9% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2025 period, LIGAND PHARMACEUTICALS INC’s cash and equivalents has grown by 508.4% (from $28.75 million to $174.93 million).
- The most recent figure is from LIGAND PHARMACEUTICALS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: